We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App





Sekisui Highlights Rapid Testing and Clinical Chemistry Solutions

By LabMedica International staff writers
Posted on 16 Nov 2026

Sekisui Diagnostics (Burlington, MA, USA) is showcasing a range of diagnostic products and raw materials at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. More...

The company's exhibit highlights four key areas: the OSOM family of rapid tests, clinical chemistry reagents, diagnostic enzymes, and blood collection tube raw materials. These offerings support healthcare providers, clinical laboratories, and diagnostic manufacturers across applications ranging from point-of-care infectious disease testing to automated laboratory analysis and specimen preparation.

Among the featured products is the OSOM Rapid Test Family, which provides point-of-care testing solutions for infectious diseases and women's health. The portfolio includes tests for influenza, Group A Streptococcus, and Trichomonas vaginalis, as well as other respiratory and infectious conditions. Designed for straightforward use with minimal hands-on steps, the tests enable healthcare providers to obtain results during a patient visit and make timely treatment decisions. Most OSOM test kits incorporate QC Inside technology, which provides additional components for performing external quality control procedures.

In clinical chemistry, Sekisui is presenting its broad range of reagents for use on automated analyzers. The portfolio includes more than 65 reagents covering cardiovascular disease, diabetes, renal and liver function, therapeutic drug monitoring, and specialty assays. Its SEKURE open-channel reagents feature liquid-stable, ready-to-use formulations compatible with a variety of clinical chemistry platforms. The company also provides calibrators, controls, and linearity materials to support consistent analytical performance and routine laboratory quality assurance.

Another focus is Sekisui's portfolio of enzymes and specialty biochemicals used in clinical chemistry assays, biosensors, and diagnostic manufacturing. Products include cholesterol oxidase and glucose dehydrogenase for applications involving lipid metabolism and glucose measurement, along with enzymes supporting renal, pancreatic, cardiovascular, and liver function testing. The company's enzyme offerings also support point-of-care devices and blood glucose monitoring systems, with manufacturing capabilities extending from research and development quantities to commercial-scale production.

Sekisui is also highlighting raw materials for plastic vacuum blood collection tubes, including serum separation gels and clotting accelerants. These materials are designed to support efficient specimen processing and reliable separation of serum from blood cells while minimizing interference with subsequent laboratory testing. Its serum separation gel provides resistance to irradiation and helps maintain stable separation of blood clots and serum. Together, the four product areas demonstrate Sekisui's involvement in both finished diagnostic tests and essential components used throughout the laboratory testing process.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.